Day One Biopharma Files 8-K on Financials

Ticker: DAWN · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1845337

Sentiment: neutral

Topics: financial-condition, operations, sec-filing

TL;DR

Day One Biopharma dropped an 8-K on July 30th covering financials and operations. Check it out.

AI Summary

On July 30, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report detailing the results of operations and financial condition. The filing also included Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Brisbane, California.

Why It Matters

This 8-K filing provides crucial updates on Day One Biopharmaceuticals' financial performance and operational status, which are key indicators for investors and stakeholders.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial condition and operations, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Day One Biopharmaceuticals, Inc., along with Regulation FD Disclosures and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on July 30, 2024.

Where are Day One Biopharmaceuticals, Inc.'s principal executive offices located?

Day One Biopharmaceuticals, Inc.'s principal executive offices are located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California, 94005.

In which U.S. state is Day One Biopharmaceuticals, Inc. incorporated?

Day One Biopharmaceuticals, Inc. is incorporated in Delaware.

What is the Standard Industrial Classification code for Day One Biopharmaceuticals, Inc.?

The Standard Industrial Classification code for Day One Biopharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 637 words · 3 min read · ~2 pages · Grade level 9.1 · Accepted 2024-07-30 07:35:27

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On July 30, 2024, Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this report. A copy of the Company's presentation with respect to its financial results for the quarter ended June 30, 2024 is attached as Exhibit 99.2 to this report.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 30 2024, the Company updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.3 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release issued by Day One Biopharmaceuticals, Inc. regarding its financial results for the quarter ended June 30, 2024, dated July 30, 2024. 99.2 Financial Results Presentation. 99.3 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: July 30, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing